Moderna Flu Vaccine Approved by US FDA for Adults 50 and Older
The Moderna flu vaccine has received approval from the US Food and Drug Administration (FDA). The decision allows the company to offer its first mRNA-based influenza vaccine to adults aged 50 and older. Moreover, Moderna plans to make the vaccine available before the 2026-2027 respiratory virus season begins.
The vaccine, called mFLUSIVA, marks another step in the use of mRNA technology. Moderna shared the update in an official statement on Wednesday. The company believes the approval will help protect older adults from seasonal influenza. In addition, officials expect supplies to be ready for eligible people across the United States before the next flu season.
FDA Changes Earlier Decision
Earlier this year, Moderna faced a setback during the approval process. In February, the company revealed that the FDA had rejected its application for review. Regulators believed the clinical trial data did not fully meet their expectations.
However, the situation changed after further discussions. Moderna described a follow-up meeting with the FDA as constructive. As a result, the agency reconsidered its earlier position and completed the approval process. Therefore, the vaccine can now enter the US market for eligible adults.
Debate Over mRNA Technology
The approval also comes during an ongoing debate about mRNA vaccines. US Health Secretary Robert F. Kennedy Jr. has questioned the technology and reduced federal research funding that supported its development. Meanwhile, the FDA has reviewed vaccine approval procedures under the current administration.
Even so, mRNA technology played a major role during the COVID-19 pandemic. Scientists used it to develop vaccines in record time. Global health authorities continue to consider those vaccines safe and effective against severe illness. Furthermore, experts say vaccination remains one of the best ways to reduce the risk of serious influenza complications. Moderna’s latest approval adds another option for older adults seeking seasonal flu protection and supports continued innovation in vaccine research worldwide.
